| ［1］ |
Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors[J]. Liver Int, 2019, 39(Suppl 1): 19–31.
|
| ［2］ |
Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma[J]. Eur J Surg Oncol, 2025, 51(2): 107064.
|
| ［3］ |
Rodrigues PM, Olaizola P, Paiva NA, et al. Pathogenesis of cholangiocarcinoma[J]. Ann Rev Pathol, 2021, 16: 433–463.
|
| ［4］ |
Lyu Z, Yu T, Zhang L, et al. Analysis of the relationship between bile duct and duodenal microbiota reveals that potential dysbacteriosis is the main cause of primary common bile duct stones[J]. Synth Syst Biotechnol, 2021, 6(4): 414–428.
|
| ［5］ |
Molinero N, Ruiz L, Milani C, et al. The human gallbladder microbiome is related to the physiological state and the biliary metabolic profile[J]. Microbiome, 2019, 7(1): 100.
|
| ［6］ |
Jin W, Xiao L, Jeong M, et al. Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity[J]. Cell, 2025, 188(9): 2336–2353.
|
| ［7］ |
Bai X, Duan Z, Deng J, et al. Ginsenoside Rh4 inhibits colorectal cancer via the modulation of gut microbiota-mediated bile acid metabolism[J]. J Adv Res, 2025, 72: 37–52.
|
| ［8］ |
Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile acid physiology[J]. Ann Hepatol, 2017, 16(Suppl. 1: s3–105.): s4-s14.
|
| ［9］ |
Ding L, Han G, Wang X, et al. Gallbladder microbiota in early vertebrates provides evolutionary insights into mucosal homeostasis[J]. Front Immunol, 2022, 13: 1020413.
|
| ［10］ |
Lehmann PV, Forsthuber T, Miller A, et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen[J]. Nature, 1992, 358(6382): 155–157.
|
| ［11］ |
Berg PA. Autoimmunity in primary biliary cirrhosis: An alternative view at initiation and function of anti-mitochondrial autoantibodies[J]. J Hepatol, 2009, 50(4): 827–828.
|
| ［12］ |
Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis[J]. Gut, 2020, 69(4): 665–672.
|
| ［13］ |
Lee J, Kim H, Park J. Beyond the bile: exploring the microbiome and metabolites in cholangiocarcinoma[J]. Life, 2024, 14(6): 698.
|
| ［14］ |
Saab M, Mestivier D, Sohrabi M, et al. Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma[J]. Plos One, 2021, 16(3): e247798.
|
| ［15］ |
Kaewpitoon SJ, Loyd RA, Rujirakul R, et al. Helicobacter species are possible risk factors of cholangiocarcinoma[J]. Asian Pac J Cancer Prev, 2016, 17(1): 37–44.
|
| ［16］ |
Park W, Lee SK, Gwack J, et al. Dysbiosis of bile microbiota in cholangiocarcinoma patients: A comparison with benign biliary diseases[J]. Int J Mol Sci, 2025, 26(4): 1577.
|
| ［17］ |
Li Z, Chu J, Su F, et al. Characteristics of bile microbiota in cholelithiasis, perihilar cholangiocarcinoma, distal cholangiocarcinoma, and pancreatic cancer[J]. Am J Transl Res, 2022, 14(5): 2962–2971.
|
| ［18］ |
桑慧, 李文洁, 周颖, 等. 胆汁酸、肠道微生物与胆管癌发生和发展关系的研究进展[J]. 中华肝脏病杂志, 2021, 29(5): 493–496.
|
| ［19］ |
Petrov VA, Fernández-Peralbo MA, Derks R, et al. Biliary microbiota and bile acid composition in cholelithiasis[J]. Biomed Res Int, 2020, 2020(1): 1242364.
|
| ［20］ |
Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J]. Nature, 2013, 499(7456): 97–101.
|
| ［21］ |
Ketpueak T, Thiennimitr P, Apaijai N, et al. Association of chronic opisthorchis infestation and microbiota alteration on tumorigenesis in cholangiocarcinoma[J]. Clin Transl Gastroenterol, 2020, 12(1): e292.
|
| ［22］ |
Petrick JL, Sahasrabuddhe VV, Chan AT, et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project[J]. Cancer Prev Res, 2015, 8(12): 1156–1162.
|
| ［23］ |
Yang H, Li TW, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression[J]. Gastroenterology, 2011, 141(1): 378–388.
|
| ［24］ |
Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis[J]. J Hepatol, 2020, 72(1): 95–103.
|
| ［25］ |
Selvaggi F, Lopetuso LR, Delli Pizzi A, et al. Diagnosis of cholangiocarcinoma: the new biological and technological horizons[J]. Diagnostics, 2025, 15(8): 1011.
|
| ［26］ |
Wu N, Bayatpour S, Hylemon PB, et al. Gut microbiome and bile acid interactions: mechanistic implications for cholangiocarcinoma development, immune resistance, and therapy[J]. Am J Pathol, 2025, 195(3): 397–408.
|
| ［27］ |
Gu D, Zhao X, Song J, et al. Expression and clinical significance of interleukin-6 pathway in cholangiocarcinoma[J]. Front Immunol, 2024, 15: 1374967.
|
| ［28］ |
Ishigami K, Nosho K, Koide H, et al. MicroRNA-31 reflects IL-6 expression in cancer tissue and is related with poor prognosis in bile duct cancer[J]. Carcinogenesis, 2018, 39(9): 1127–1134.
|
| ［29］ |
Degand N, Dautremer J, Pilmis B, et al. Helicobacter bilis-associated suppurative cholangitis in a patient with X-linked agammaglobulinemia[J]. J Clin Immunol, 2017, 37(7): 727–731.
|
| ［30］ |
Yamashita M, Adachi T, Ono S, et al. Helicobacter bilis infection induces oxidative stress in and enhances the proliferation of human cholangiocytes[J]. Helicobacter, 2022, 27(4): e12908.
|
| ［31］ |
Chen F, Sheng J, Li X, et al. Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression[J]. Front Immunol, 2024, 15: 1451474.
|
| ［32］ |
Yang L, Han P, Cui T, et al. M2 macrophage inhibits the antitumor effects of lenvatinib on intrahepatic cholangiocarcinoma[J]. Front Immunol, 2023, 14: 1251648.
|
| ［33］ |
Zhang Y, Chen S, Li J, et al. Immune infiltrating cells in cholangiocarcinoma may become clinical diagnostic markers: based on bioinformatics analysis[J]. World J Surg Oncol, 2021, 19(1): 59.
|
| ［34］ |
Liu D, Heij LR, Czigany Z, et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2022, 41(1): 127.
|
| ［35］ |
Zhang G, Li J, Li G, et al. Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions[J]. Clin Exp Med, 2024, 24(1): 193.
|
| ［36］ |
Poudel SK, Padmanabhan R, Dave H, et al. Microbiomic profiles of bile in patients with benign and malignant pancreaticobiliary disease[J]. Plos One, 2023, 18(4): e283021.
|
| ［37］ |
Wang J, Liu Q, Jin S, et al. Characterization of bile microbiota in patients with obstructive jaundice associated with biliary tract diseases[J]. Clin Transl Gastroenterol, 2025, 16(7): e841.
|
| ［38］ |
李丹. 胆总管结石与胆管癌患者胆道菌群对比研究[D]. 延安: 延安大学, 2021: 18.
|
| ［39］ |
Wang L, Zhao H, Wu F, et al. Bile-liver phenotype: exploring the microbiota landscape in bile and intratumor of cholangiocarcinoma[J]. Comput Struct Biotechnol J, 2025, 27: 1173–1186.
|
| ［40］ |
Grigor Eva IN, Romanova TI. Gallstone disease and microbiome[J]. Microorganisms, 2020, 8(6): 835.
|
| ［41］ |
Chen X, Sun S, Yan X, et al. Predictive factors and microbial spectrum for infectious complications after hepatectomy with cholangiojejunostomy in perihilar cholangiocarcinoma[J]. Surg Infect, 2020, 21(3): 275–283.
|
| ［42］ |
Picardo SL, Coburn B, Hansen AR. The microbiome and cancer for clinicians[J]. Crit Rev Oncol Hematol, 2019, 141: 1–12.
|
| ［43］ |
Riquelme E, Zhang Y, Zhang L, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes[J]. Cell, 2019, 178(4): 795–806.
|
| ［44］ |
Özdirik B, Müller T, Wree A, et al. The role of microbiota in primary sclerosing cholangitis and related biliary malignancies[J]. Int J Mol Sci, 2021, 22(13): 6975.
|
| ［45］ |
Tan N, Lubel J, Kemp W, et al. Current therapeutics in primary sclerosing cholangitis[J]. J Clin Transl Hepatol, 2023, 11(5): 1267–1281.
|
| ［46］ |
Qin H, Yuan B, Huang W, et al. Utilizing gut microbiota to improve hepatobiliary tumor treatments: recent advances[J]. Front Oncol, 2022, 12: 924696.
|